Trials / Completed
CompletedNCT05133752
Oral Nemonoxacin in Treating Elderly Patients With CAP
A Multi-Center, Open-Label, Single-Arm, Phase IV Study to Evaluate the Safety and Clinical Efficacy of Oral Administration With Nemonoxacin in Treating Elderly Patients With Community-Acquired Pneumonia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- TaiGen Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
This study was to evaluate the safety and efficacy of oral nemonoxacin in treating elderly patients (aged ≥ 65 years) with community-acquired pneumonia (CAP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nemonoxacin | 500 mg, oral administration, once daily for 7-10 days. |
Timeline
- Start date
- 2018-09-11
- Primary completion
- 2020-03-23
- Completion
- 2020-03-23
- First posted
- 2021-11-24
- Last updated
- 2021-11-24
Locations
1 site across 1 country: Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05133752. Inclusion in this directory is not an endorsement.